Treatment de-intensification for low-risk biochemical recurrence after radical prostatectomy: rational or risky?

BJU InternationalEarly View Comment Treatment de-intensification for low-risk biochemical recurrence after radical prostatectomy: rational or risky? Matthew J. Roberts, Corresponding Author Matthew J. Roberts [email protected] orcid.org/0000-0003-0552-7402 Department of Urology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia Faculty of Medicine, University of Queensland Centre for Clinical Research, Brisbane, Queensland, Australia Correspondence: Matthew Roberts, Department of Urology, Royal Brisbane and Women's Hospital, Brisbane, Queensland 4006, Australia. e-mail: [email protected]Search for more papers by this authorGeorge Hruby, George Hruby Department of Radiation Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia Genesis Cancer Care, Sydney, New South Wales, AustraliaSearch for more papers by this authorAndrew Kneebone, Andrew Kneebone Department of Radiation Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia Genesis Cancer Care, Sydney, New South Wales, AustraliaSearch for more papers by this authorJarad M. Martin, Jarad M. Martin Department of Radiation Oncology, Calvary Mater Newcastle, Waratah, New South Wales, Australia Genesis Care, Maitland, Metford, New South Wales, AustraliaSearch for more papers by this authorScott G. Williams, Scott G. Williams Sir Peter MacCallum Department of Oncology, Melbourne University, Parkville, Victoria, Australia Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, AustraliaSearch for more papers by this authorMark Frydenberg, Mark Frydenberg Department of Surgery, Department of Anatomy and Developmental Biology, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia Cabrini Research, Cabrini Health, Melbourne, Victoria, AustraliaSearch for more papers by this authorDeclan G. Murphy, Declan G. Murphy orcid.org/0000-0002-7500-5899 Sir Peter MacCallum Department of Oncology, Melbourne University, Parkville, Victoria, Australia Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, AustraliaSearch for more papers by this authorBen Namdarian, Ben Namdarian St Vincent's Hospital, Darlinghurst, Sydney, New South Wales, AustraliaSearch for more papers by this authorJohn W. Yaxley, John W. Yaxley Department of Urology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia Faculty of Medicine, University of Queensland Centre for Clinical Research, Brisbane, Queensland, AustraliaSearch for more papers by this authorMichael S. Hofman, Michael S. Hofman orcid.org/0000-0001-8622-159X Sir Peter MacCallum Department of Oncology, Melbourne University, Parkville, Victoria, Australia Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Victoria, Melbourne, AustraliaSearch for more papers by this authorIan D. Davis, Ian D. Davis Eastern Health Clinical School, Monash University, Victoria, Melbourne, Australia Department of Cancer Services, Eastern Health, Melbourne, Victoria, AustraliaSearch for more papers by this authorLouise Emmett, Louise Emmett Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia Faculty of Medicine, University of New South Wales, Sydney, New South Wales, AustraliaSearch for more papers by this author Matthew J. Roberts, Corresponding Author Matthew J. Roberts [email protected] orcid.org/0000-0003-0552-7402 Department of Urology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia Faculty of Medicine, University of Queensland Centre for Clinical Research, Brisbane, Queensland, Australia Correspondence: Matthew Roberts, Department of Urology, Royal Brisbane and Women's Hospital, Brisbane, Queensland 4006, Australia. e-mail: [email protected]Search for more papers by this authorGeorge Hruby, George Hruby Department of Radiation Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia Genesis Cancer Care, Sydney, New South Wales, AustraliaSearch for more papers by this authorAndrew Kneebone, Andrew Kneebone Department of Radiation Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia Genesis Cancer Care, Sydney, New South Wales, AustraliaSearch for more papers by this authorJarad M. Martin, Jarad M. Martin Department of Radiation Oncology, Calvary Mater Newcastle, Waratah, New South Wales, Australia Genesis Care, Maitland, Metford, New South Wales, AustraliaSearch for more papers by this authorScott G. Williams, Scott G. Williams Sir Peter MacCallum Department of Oncology, Melbourne University, Parkville, Victoria, Australia Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, AustraliaSearch for more papers by this authorMark Frydenberg, Mark Frydenberg Department of Surgery, Department of Anatomy and Developmental Biology, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia Cabrini Research, Cabrini Health, Melbourne, Victoria, AustraliaSearch for more papers by this authorDeclan G. Murphy, Declan G. Murphy orcid.org/0000-0002-7500-5899 Sir Peter MacCallum Department of Oncology, Melbourne University, Parkville, Victoria, Australia Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, AustraliaSearch for more papers by this authorBen Namdarian, Ben Namdarian St Vincent's Hospital, Darlinghurst, Sydney, New South Wales, AustraliaSearch for more papers by this authorJohn W. Yaxley, John W. Yaxley Department of Urology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia Faculty of Medicine, University of Queensland Centre for Clinical Research, Brisbane, Queensland, AustraliaSearch for more papers by this authorMichael S. Hofman, Michael S. Hofman orcid.org/0000-0001-8622-159X Sir Peter MacCallum Department of Oncology, Melbourne University, Parkville, Victoria, Australia Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Victoria, Melbourne, AustraliaSearch for more papers by this authorIan D. Davis, Ian D. Davis Eastern Health Clinical School, Monash University, Victoria, Melbourne, Australia Department of Cancer Services, Eastern Health, Melbourne, Victoria, AustraliaSearch for more papers by this authorLouise Emmett, Louise Emmett Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia Faculty of Medicine, University of New South Wales, Sydney, New South Wales, AustraliaSearch for more papers by this author First published: 22 May 2023 https://doi.org/10.1111/bju.16086Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. References 1Mottet N, Bellmunt J, Briers E et al. EAU – ESTRO – ESUR – SIOG Guidelines on Prostate Cancer. Arnhem, The Netherlands: EAU Guidelines Office, 2022 2Adam M, Tennstedt P, Lanwehr D et al. Functional outcomes and quality of life after radical prostatectomy only versus a combination of prostatectomy with radiation and hormonal therapy. Eur Urol 2017; 71: 330– 6 3Fendler WP, Calais J, Eiber M et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: A prospective single-arm clinical trial. JAMA Oncol 2019; 5: 856– 63 4Emmett L, Tang R, Nandurkar R et al. 3-year freedom from progression after (68)Ga-PSMA PET/CT-triaged Management in men with biochemical recurrence after radical prostatectomy: Results of a prospective multicenter trial. J Nucl Med 2020; 61: 866– 72 5Roberts MJ, Chatfield MD, Hruby G et al. Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups. BJU Int 2022; 130(Suppl 3): 32– 9 6Jani AB, Schreibmann E, Goyal S et al. 18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): A single Centre, open-label, phase 2/3 randomised controlled trial. Lancet 2021; 397: 1895– 904 Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation